- Home
- CLLS vs AVTX Comparison
CLLS vs AVTX Comparison
Compare CLLS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | AVTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 248.3M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLLS | AVTX |
|---|---|---|
| Price | $4.39 | $18.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $8.00 | ★ $32.29 |
| AVG Volume (30 Days) | 132.4K | ★ 325.1K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,551,000.00 | $192,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $3.39 |
| 52 Week High | $5.48 | $20.72 |
Technical Indicators
Market Signals| Indicator | CLLS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 55.48 |
| Support Level | $4.47 | $17.18 |
| Resistance Level | $5.45 | $20.20 |
| Average True Range (ATR) | 0.30 | 1.59 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 31.17 | 65.70 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).